
    
      The protocol posting has been amended to reflect the two new vaccine presentations that have
      been launched in Korea. The current PMS will thus collect safety information from subjects
      who have received either Rotarix or Rotarix liquid formulation (oral suspension or prefilled
      syringe) in the course of their routine clinical practice according to the prescribing
      information in Korea.
    
  